Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

NCT ID: NCT02153229

Last Updated: 2025-12-26

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-02
• Study Completion Date: 2027-12-31

Brief Summary

A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.

Conditions

Epitheliod Malignant Pleural Mesothelioma

Keywords

Histological diagnosis of MPM; epitheliod subtype; limited to the hemithorax; macroscopically complete resection of the tumor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

patients who undergo RP plus photofrin-based PDT

Group Type: EXPERIMENTAL

Photodynamic Therapy

Intervention Type: RADIATION

Radical Pleurectomy

Intervention Type: PROCEDURE

Chemotherapy

Intervention Type: RADIATION

Photofrin 2.0 mg/kg

Intervention Type: DRUG

If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy

patients who undergo RP alone

Group Type: EXPERIMENTAL

Radical Pleurectomy

Intervention Type: PROCEDURE

Chemotherapy

Intervention Type: RADIATION

Interventions

Photodynamic Therapy

Intervention Type: RADIATION

Radical Pleurectomy

Intervention Type: PROCEDURE

Chemotherapy

Intervention Type: RADIATION

Photofrin 2.0 mg/kg

If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy

Intervention Type: DRUG

Other Intervention Names

PDT; RP

Eligibility Criteria

Inclusion Criteria

• Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumor.
• Patients must have disease limited to the hemithorax.
• Patients who have received prior surgery, gene therapy, or combination chemotherapy will be permitted if it has been at least 30 days since the last treatment.
• Subjects treated with pemetrexed previously will be eligible only if 30 days have elapsed between the last dose of pemetrexed and the date of surgery.
• ECOG performance status of 0-1.
• Medical suitability for resection, including documented medical and cardiac clearance.
• 18 years of age or older.
• Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks. Patients unwilling or unable due to cognitive impairment to sign informed consent are excluded from the study.

Exclusion Criteria

• Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer
• Pregnant or lactating patients.
• Patients who have a history of HIV disease.
• Patients who have a white count less than 2,500 per cubic mm or platelets less than 100,000/cubic mm.
• Serum creatinine equal or greater than 2.5 mg/deciliter.
• Patients who have severe liver disease including cirrhosis, Grade III-IV elevations in liver function studies, or bilirubin in excess of 1.5 mg/deciliter.
• Patients with porphyria or hypersensitivity to porphyrin or porphyrin-like compounds.
• Patients who have been treated with pemetrexed if the last dose of pemetrexed is < 30 days to the date of surgery.
• Patients that have been treated with prior Mantle field radiation.
• Patients with distant metastatic disease or otherwise not confined to the ipsilateral hemithorax.
• Subjects who have received more than 2 doses of neo-adjuvant chemotherapy

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abramson Cancer Center at Penn Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Keith Cengel, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Abramson Cancer Center at Penn Medicine

Locations

Roswell Park Cancer Institute

Buffalo, New York, United States

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

Other Identifiers

UPCC 14513

Identifier Type: -

Identifier Source: org_study_id